Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 3/20 | 0.72 |
| ▸ | CA1 | P00915 | 3/20 | 0.72 |
| ▸ | CA2 | P00918 | 3/20 | 0.72 |
| ▸ | CA7 | P43166 | 3/20 | 0.72 |
| ▸ | CA9 | Q16790 | 3/20 | 0.72 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.72 |
| ▸ | TYR | P14679 | 1/20 | 0.72 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.62 |
| ▸ | TTR | P02766 | 1/20 | 0.61 |
| ▸ | APP | P05067 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.54 |
| ▸ | JAK2 | O60674 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | FDPS | P14324 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20654 | 1.00 | CA12 (0.72) | CA12CA1CA2CA7CA9 | |
| Hydrochloric Acid SCHEMBL724881 | 0.98 | CA12 (0.70) | CA12CA1CA2CA7CA9 | |
| Hydrochloric Acid SCHEMBL724882 | 0.98 | CA12 (0.70) | CA12CA1CA2CA7CA9 | |
| SCHEMBL71224 | 0.92 | CA12 (0.84) | CA12CA1CA2CA7CA9 | |
| SCHEMBL5057418 | 0.92 | CA12 (0.84) | CA12CA1CA2CA7CA9 | |
| E-Methyl Cinnamate SCHEMBL5487325 | 0.91 | KMT2A (0.68) | CA12CA1CA2CA7CA9 | |
| E-Methyl Cinnamate SCHEMBL5487323 | 0.91 | KMT2A (0.68) | CA12CA1CA2CA7CA9 | |
| SCHEMBL4429179 | 0.90 | ALDH1A1 (0.61) | CA12CA1CA2CA7CA9 | |
| SCHEMBL4429187 | 0.90 | ALDH1A1 (0.61) | CA12CA1CA2CA7CA9 | |
| SCHEMBL4429182 | 0.88 | ALDH1A1 (0.62) | CA12CA1CA2CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 327 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109232541-B | Prolyl hydroxylase and histone deacetylase dual inhibitor and preparation method and application thereof | 中国医学科学院放射医学研究所 | 2020-04-24 | — | — | CN | claimed |
| WO-2018092151-A1 | PROCESS FOR THE PREPARATION OF 2-(E)-N-HYDROXY-3-[4-[[[2-(2-METHYL-1H-INDOL-3-YL) ETHYL]AMINO]METHYL]PHENYL]-2-PROPENAMIDE 2-HYDROXYPROPANOIC ACID (1:1) AND ITS POLYMORPHS THEREOF | MSN LABORATORIES PRIVATE LIMITED, R&D CENTER (IN) | 2018-05-24 | — | — | WO | claimed |
| CN-106674079-A | Synthesis method of panobinostat | 南京卡文迪许生物工程技术有限公司 | 2017-05-17 | — | — | CN | claimed |
| EP-2394991-B1 | Process for making starting materials for N-hydroxy-3-[4-[2-(2-methyl-1 H-indol-3-yl)-ethylaminomethyl]-phenyl]-2E-2-propenamide | NOVARTIS AG (CH) | 2015-09-23 | — | — | EP | claimed |
| US-8536346-B2 | Process or making N-hydroxy-3[4-[[[2-(2methyl-1H-indol-3-yl)ethyl]amino]methyl]phenyl]-2E-2-propenamide and starting materials therefor | NOVARTIS AG (CH) | 2013-09-17 | — | — | US | claimed |
| US-20120010418-A1 | Process for Making N-Hydroxy-3[4-[[[2-(2methyl-1H-indol-3-yl)ethyl]amino]methyl]phenyl]-2E-2-propenamide and Starting Materials Therefor | NOVARTIS AG (CH) | 2012-01-12 | — | — | US | claimed |
| EP-2394991-A1 | Process for making n-hydroxy-3-ü4-üüü2-(2-methyl-1h-indol-3-yl)ethyl¨amino¨methyl¨phenyl¨-2e-2-propenamide and starting materials therefor | Novartis AG (CH) | 2011-12-14 | — | — | EP | claimed |
| US-20090306405-A1 | PROCESS FOR MAKING N-HYDROXY-3-[4-[[[2-(2-METHYL-1H-INDOL-3-YL)ETHYL]AMINO]METHYL]PHENYL]-2E-2-PROPENAMIDE AND STARTING MATERIALS THEREFOR | NOVARTIS AG (CH) | 2009-12-10 | — | — | US | claimed |
| EP-2032533-A2 | PROCESS FOR MAKING N-HYDROXY-3-Ý4-ÝÝÝ2-(2-METHYL-1H-INDOL-3-YL)ETHYL¨AMINO¨METHYL¨PHENYL¨-2E-2-PROPENAMIDE AND STARTING MATERIALS THEREFOR | Novartis AG (CH) | 2009-03-11 | — | — | EP | claimed |
| WO-2007146718-A2 | PROCESS FOR MAKING N-HYDROXY-3-[4-[[[2-(2-METHYL-1H-INDOL-3-YL)ETHYL]AMINO] METHYL]PHENYL]-2E-2-PROPENAMIDE AND STARTING MATERIALS THEREFOR | NOVARTIS AG (CH) | 2007-12-21 | — | — | WO | claimed |
| US-12491270-B2 | Imaging histone deacetylases with a radiotracer using positron emission tomography | THE GENERAL HOSPITAL CORPORATION (US) | 2025-12-09 | — | — | US | disclosed |
| US-12479797-B2 | Cyclopropyl-amide compounds as dual LSD1/HDAC inhibitors | Jubilant Epicore LLC (US) | 2025-11-25 | — | — | US | disclosed |
| US-20250346563-A1 | HISTONE DEACETYLASE 6 INHIBITORS AND METHOD FOR TREATING NEUROPATHIC PAIN | UNIV TAIPEI MEDICAL (TW) | 2025-11-13 | — | — | US | disclosed |
| EP-3455204-B1 | CYCLOPROPYL-AMIDE COMPOUNDS AS DUAL LSD1/HDAC INHIBITORS | Jubilant Epicore LLC (US) | 2025-10-29 | — | — | EP | disclosed |
| US-20250304549-A1 | HYDROXYAMIDE DERIVATIVE AND USE THEREOF | SICHUAN HUIYU PHARMACEUTICAL CO., LTD. (CN) | 2025-10-02 | — | — | US | disclosed |
| US-4346016-A | FOR NATURAL AND SYNTHETIC POLYMERS | CIBA-GEIGY CORPORATION (US) | 1982-08-24 | — | — | US | disclosed |
| US-4309443-A | ANTI-OBESITY, HYPOGLYCEMIC | BEECHAM GROUP LIMITED (GB) | 1982-01-05 | — | — | US | disclosed |
| EP-0025331-A1 | Cinnamic acid derivatives, their preparation, and pharmaceutical compositions containing them | BEECHAM GROUP PLC (GB) | 1981-03-18 | — | — | EP | disclosed |
| US-4196229-A | NITRILES, ESTERS, AMIDES, SULFONES, AND KETONES | SANDOZ LTD. (CH) | 1980-04-01 | — | — | US | disclosed |
| US-4108887-A | Divinyl stilbenes as optical brighteners | SANDOZ LTD. (CH) | 1978-08-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12491270-B2 | Imaging histone deacetylases with a radiotracer using positron emission tomography | HDAC1, HDAC11, HDAC3 | CA12 317/4885CA1 195/4885CA2 2377/4885 |
| US-20250346563-A1 | HISTONE DEACETYLASE 6 INHIBITORS AND METHOD FOR TREATING NEUROPATHIC PAIN | HDAC1, HDAC3, HDAC5 | CA12 1559/4885CA1 479/4885CA2 719/4885 |
| US-12479797-B2 | Cyclopropyl-amide compounds as dual LSD1/HDAC inhibitors | HDAC1, HDAC11, HDAC2 | CA12 3079/4885CA1 1041/4885CA2 1873/4885 |
| US-20090306405-A1 | PROCESS FOR MAKING N-HYDROXY-3-[4-[[[2-(2-METHYL-1H-INDOL-3-YL)ETHYL]AMINO]METHYL]PHENYL]-2E-2-PROPENAMIDE AND STARTING MATERIALS THEREFOR | WEE2, WEE1, HASPIN | CA12 4432/4885CA1 4177/4885CA2 4107/4885 |
| US-20250304549-A1 | HYDROXYAMIDE DERIVATIVE AND USE THEREOF | HDAC1, HDAC11, HDAC5 | CA12 1730/4885CA1 740/4885CA2 942/4885 |
| US-20120010418-A1 | Process for Making N-Hydroxy-3[4-[[[2-(2methyl-1H-indol-3-yl)ethyl]amino]methyl]phenyl]-2E-2-propenamide and Starting Materials Therefor | PNMT, HTR1B, WEE2 | CA12 4009/4885CA1 3594/4885CA2 3453/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.